Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8937505 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937509 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937299 | 0.92 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937302 | 0.92 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937535 | 0.92 | ALDH1A1 (0.64) | ALDH1A1LMNAKDM4EL3MBTL1KMT2A | |
| SCHEMBL8937542 | 0.92 | ALDH1A1 (0.64) | ALDH1A1LMNAKDM4EL3MBTL1KMT2A | |
| SCHEMBL8937608 | 0.84 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937466 | 0.84 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937461 | 0.84 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL8937415 | 0.84 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ESMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | claimed |
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |